Hawthorne Benjamin, Lund Kaleb, Freggiaro Sydney, Kaga Risa, Meng Jing
School of Naturopathic Medicine, Bastyr University, 14500 Juanita Drive NE, Kenmore, WA 98028, USA.
School of Natural Health Arts & Sciences, Bastyr University, 14500 Juanita Drive NE, Kenmore, WA 98028, USA.
Biomed Pharmacother. 2022 May;149:112887. doi: 10.1016/j.biopha.2022.112887. Epub 2022 Mar 31.
Panax notoginseng (Burkill) F.H. commonly referred to as Sanqi, is a Chinese herb that has long been used to treat various conditions including blood disorders and cardiovascular diseases. While Panax notoginseng has been used as an anti-cancer medicinal herb in recent years, how it achieves this therapeutic effect has not been thoroughly elucidated. The purpose of this study was to reveal more about the mechanism of the cytotoxic effect of Panax notoginseng on prostate cancer (PCa) cells.
Ethanol extract of Panax notoginseng root was authenticated using high-performance liquid chromatography (HPLC). The cytotoxic activity of this herb against PCa cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, flow cytometry, and enzyme-linked immunosorbent assay (ELISA).
The assessment of cellular metabolic activity demonstrated that Panax notoginseng reduces the viability of LNCaP and 22Rv1 cells in a dose-dependent manner. Annexin-V binding flow cytometry assay showed that Panax notoginseng induces apoptosis in PCa cells. Cell cycle analysis by quantification of DNA content using flow cytometry showed that Panax notoginseng arrests the cell cycle at the G2/M phase in both LNCaP and 22Rv1 cells. Moreover, ELISA demonstrated that Panax notoginseng-treated PCa cells secrete significantly less tumor-promoting cytokine interleukin-4 (IL-4) to the supernatant compared with controls.
These results provide evidence for the cytotoxic effects of Panax notoginseng on PCa cell lines. This botanical is a promising candidate for the complementary and integrative medicine treatment of PCa and further studies are indicated to determine the anti-cancer mechanism of Panax notoginseng.
三七,通常被称为“Sanqi”,是一种长期以来用于治疗包括血液疾病和心血管疾病在内的各种病症的中药材。近年来,三七被用作抗癌草药,但其实现这种治疗效果的机制尚未得到充分阐明。本研究的目的是更深入地揭示三七对前列腺癌细胞的细胞毒性作用机制。
采用高效液相色谱法(HPLC)对三七根乙醇提取物进行鉴定。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)法、流式细胞术和酶联免疫吸附测定(ELISA)来测定该草药对前列腺癌细胞的细胞毒性活性。
细胞代谢活性评估表明,三七以剂量依赖性方式降低LNCaP和22Rv1细胞的活力。膜联蛋白-V结合流式细胞术检测显示,三七诱导前列腺癌细胞凋亡。通过流式细胞术定量DNA含量进行的细胞周期分析表明,三七使LNCaP和22Rv1细胞的细胞周期停滞在G2/M期。此外,ELISA表明,与对照组相比,经三七处理的前列腺癌细胞向上清液中分泌的促肿瘤细胞因子白细胞介素-4(IL-4)显著减少。
这些结果为三七对前列腺癌细胞系的细胞毒性作用提供了证据。这种植物是前列腺癌补充和综合医学治疗的有希望的候选者,表明需要进一步研究以确定三七的抗癌机制。